MI-219-zinc combination: A new paradigm in MDM2 inhibitor-based therapy

Oncogene

Volumn 30, Issue 1, 2011, Pages 117-126

  Azmi, A S ^a   Philip, P A ^a   Beck, F W J ^a   Wang, Z ^a   Banerjee, S ^a   Wang, S ^b,c   Yang, D ^c   Sarkar, F H ^a   Mohammad, R M ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c Ascenta Therapeutics   (United States)

Author keywords

apoptosis; MDM2 and p53; small molecule inhibitors; zinc

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; DNA; ETHYLENE GLYCOL 1,2 BIS(2 AMINOPHENYL) ETHER N,N,N',N' TETRAACETIC ACID; LIGASE INHIBITOR; MI 219; N,N,N',N' TETRAKIS(2 PYRIDYLMETHYL)ETHYLENEDIAMINE; PROTEIN BAX; PROTEIN MDM2; PROTEIN P53; UNCLASSIFIED DRUG; ZINC; ZINC CHLORIDE;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CHELATION; COLON CANCER; COLONY FORMATION; CONTROLLED STUDY; DOWNSTREAM PROCESSING; ELDERLY CARE; FEEDBACK SYSTEM; HIGH RISK POPULATION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROTEIN MODIFICATION; RING FINGER MOTIF; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; ZINC DEFICIENCY;

APOPTOSIS; BREAST NEOPLASMS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL NUCLEUS; CHELATING AGENTS; CHLORIDES; COLONIC NEOPLASMS; DRUG SYNERGISM; ENZYME INHIBITORS; HCT116 CELLS; HUMANS; PROTO-ONCOGENE PROTEINS C-MDM2; TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53; ZINC COMPOUNDS;

EID: 78650978663     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.403     Document Type: Article

References (51)

1. Alshatwi AA, Han CT, Schoene NW, Lei KY. (2006). Nuclear accumulations of p53 and Mdm2 are accompanied by reductions in c-Abl and p300 in zinc-depleted human hepatoblastoma cells. Exp Biol Med (Maywood) 231: 611-618.
2. Azmi AS, Aboukameel A, Banerjee S, Wang Z, Mohammad M, Wu J et al. (2010). MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function. Eur J Cancer 46: 1122-1131.
3. Azmi AS, Wang Z, Burikhanov R, Rangnekar VM, Wang G, Chen J et al. (2008). Critical role of prostate apoptosis response-4 in determining the sensitivity of pancreatic cancer cells to small-molecule inhibitor-induced apoptosis. Mol Cancer Ther 7: 2884-2893.
4. Bao B, Prasad A, Beck FW, Suneja A, Sarkar F. (2006). Toxic effect of zinc on NF-kappaB, IL-2, IL-2 receptor alpha, and TNF-alpha in HUT-78 (Th(0)) cells. Toxicol Lett 166: 222-228.
5. Bargonetti J, Manfredi JJ, Chen X, Marshak DR, Prives C. (1993). A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein. Genes Dev 7: 2565-2574.
6. Beck FW, Prasad AS, Butler CE, Sakr WA, Kucuk O, Sarkar FH. (2004). Differential expression of hZnT-4 in human prostate tissues. Prostate 58: 374-381.
7. Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP. (2009). Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer 9: 862-873.
8. Brown KH, Rivera JA, Bhutta Z, Gibson RS, King JC, Lonnerdal B et al. (2004). International Zinc Nutrition Consultative Group (IZiNCG) technical document. Food Nutr Bull 25: S99-203.
9. Butler JS, Loh SN. (2003). Structure, function, and aggregation of the zinc-free form of the p53 DNA binding domain. Biochemistry 42: 2396-2403.
10. Butler JS, Loh SN. (2007). Zn(2+)-dependent misfolding of the p53 DNA binding domain. Biochemistry 46: 2630-2639.
11. Canner JA, Sobo M, Ball S, Hutzen B, DeAngelis S, Willis W et al. (2009). MI-63: a novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53. Br J Cancer 101: 774-781.
12. Chen GD, Chou CM, Hwang SP, Wang FF, Chen YC, Hung CC et al. (2006). Requirement of nuclear localization and transcriptional activity of p53 for its targeting to the yolk syncytial layer (YSL) nuclei in zebrafish embryo and its use for apoptosis assay. Biochem Biophys Res Commun 344: 272-282.
13. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. (1994). Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumori-genic mutations. Science 265: 346-355.
14. Christianson DW. (1991). Structural biology of zinc. Adv Protein Chem 42: 281-355.
15. Collins K, Jacks T, Pavletich NP. (1997). The cell cycle and cancer. Proc Natl Acad Sci USA 94: 2776-2778.
16. Ding K, Lu Y, Nikolovska-Coleska Z, Qiu S, Ding Y, Gao W et al. (2005). Structure-based design of potent non-peptide MDM2 inhibitors. J Am Chem Soc 127: 10130-10131.
17. Ding K, Lu Y, Nikolovska-Coleska Z, Wang G, Qiu S, Shangary S et al. (2006). Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. J Med Chem 49: 3432-3435.
18. Feng Z, Hu W, Rajagopal G, Levine AJ. (2008). The tumor suppressor p53: cancer and aging. Cell Cycle 7: 842-847.
19. Giannakakou P, Nakano M, Nicolaou KC, O'Brate A, Yu J, Blagosklonny MV et al. (2002). Enhanced microtubule-dependent trafficking and p53 nuclear accumulation by suppression of microtubule dynamics. Proc Natl Acad Sci USA 99: 10855-10860.
20. Hambidge KM, Krebs NF, Miller L. (1998). Evaluation of zinc metabolism with use of stable-isotope techniques: implications for the assessment of zinc status. Am J Clin Nutr 68: 410S-413S.
21. Ho E. (2004). Zinc deficiency, DNA damage and cancer risk. J Nutr Biochem 15: 572-578.
22. Ho E, Ames BN. (2002). Low intracellular zinc induces oxidative DNA damage, disrupts p53, NFkappa B, and AP1 DNA binding, and affects DNA repair in a rat glioma cell line. Proc Natl Acad Sci USA 99: 16770-16775.
23. Ho E, Song Y. (2009). Zinc and prostatic cancer. Curr Opin Clin Nutr Metab Care 12: 640-645.
24. Itahana K, Mao H, Jin A, Itahana Y, Clegg HV, Lindstrom MS et al. (2007). Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation. Cancer Cell 12: 355-366.
25. Kubbutat MH, Jones SN, Vousden KH. (1997). Regulation of p53 stability by Mdm2. Nature 387: 299-303.
26. Lane DP, Fischer PM. (2004). Turning the key on p53. Nature 427: 789-790.
27. Levine AJ. (1997). p53, the cellular gatekeeper for growth and division. Cell 88: 323-331.
28. Levine AJ, Wu MC, Chang A, Silver A, Attiyeh EF, Lin J et al. (1995). The spectrum of mutations at the p53 locus. Evidence for tissue-specific mutagenesis, selection of mutant alleles, and a "gain of function" phenotype. Ann N Y Acad Sci 768: 111-128.
29. Lindstrom MS, Jin A, Deisenroth C, White WG, Zhang Y. (2007). Cancer-associated mutations in the MDM2 zinc finger domain disrupt ribosomal protein interaction and attenuate MDM2-induced p53 degradation. Mol Cell Biol 27: 1056-1068.
30. Marine JC, Lozano G. (2010). Mdm2-mediated ubiquitylation: p53 and beyond. Cell Death Differ 17: 93-102.
31. Meek DW. (1998). Multisite phosphorylation and the integration of stress signals at p53. Cell Signal 10: 159-166.
32. Meplan C, Richard MJ, Hainaut P. (2000). Metalloregulation of the tumor suppressor protein p53: zinc mediates the renaturation of p53 after exposure to metal chelators in vitro and in intact cells. Oncogene 19: 5227-5236.
33. Meplan C, Verhaegh G, Richard MJ, Hainaut P. (1999). Metal ions as regulators of the conformation and function of the tumour suppressor protein p53: implications for carcinogenesis. Proc Nutr Soc 58: 565-571.
34. Mohammad RM, Wu J, Azmi AS, Aboukameel A, Sosin A, Wu S et al. (2009). An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals. Mol Cancer 8: 115.
35. O'Brate A, Giannakakou P. (2003). The importance of p53 location: nuclear or cytoplasmic zip code? Drug Resist Updat 6: 313-322.
36. Pavletich NP, Chambers KA, Pabo CO. (1993). The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. Genes Dev 7: 2556-2564.
37. Prasad AS. (2001). Discovery of human zinc deficiency: impact on human health. Nutrition 17: 685-687.
38. Prasad AS. (2004). Zinc deficiency: its characterization and treatment. Met Ions Biol Syst 41: 103-137.
39. Prasad AS, Bao B, Beck FW, Sarkar FH. (2001). Zinc activates NF-kappaB in HUT-78 cells. J Lab Clin Med 138: 250-256.
40. Prasad AS, Bao B, Beck FW, Sarkar FH. (2002). Zinc enhances the expression of interleukin-2 and interleukin-2 receptors in HUT-78 cells by way of NF-kappaB activation. J Lab Clin Med 140: 272-289.
41. Prasad AS, Fitzgerald JT, Hess JW, Kaplan J, Pelen F, Dardenne M. (1993). Zinc deficiency in elderly patients. Nutrition 9: 218-224.
42. Shangary S, Qin D, McEachern D, Liu M, Miller RS, Qiu S et al. (2008). Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci USA 105: 3933-3938.
43. Shangary S, Wang S. (2009). Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu Rev Pharmacol Toxicol 49: 223-241.
44. Vassilev LT. (2007). MDM2 inhibitors for cancer therapy. Trends Mol Med 13: 23-31.
45. Verhaegh GW, Parat MO, Richard MJ, Hainaut P. (1998). Modulation of p53 protein conformation and DNA-binding activity by intracellular chelation of zinc. Mol Carcinog 21: 205-214.
46. Verma R, Rigatti MJ, Belinsky GS, Godman CA, Giardina C. (2010). DNA damage response to the Mdm2 inhibitor nutlin-3. Biochem Pharmacol 79: 565-574.
47. Wallace M, Worrall E, Pettersson S, Hupp TR, Ball KL. (2006). Dual-site regulation of MDM2 E3-ubiquitin ligase activity. Mol Cell 23: 251-263.
48. Wawrzynow B, Pettersson S, Zylicz A, Bramham J, Worrall E, Hupp TR et al. (2009). A function for the RING finger domain in the allosteric control of MDM2 conformation and activity. J Biol Chem 284: 11517-11530.
49. Yu S, Qin D, Shangary S, Chen J, Wang G, Ding K et al. (2009). Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction. J Med Chem 52: 7970-7973.
50. Zalewski PD, Forbes IJ, Betts WH. (1993). Correlation of apoptosis with change in intracellular labile Zn(II) using zinquin [(2-methyl-8-p- toluenesulphonamido-6-quinolyloxy)acetic acid], a new specific fluorescent probe for Zn(II). Biochem J 296(Part 2): 403-408.
51. Zalewski PD, Forbes IJ, Seamark RF, Borlinghaus R, Betts WH, Lincoln SF et al. (1994). Flux of intracellular labile zinc during apoptosis (gene-directed cell death) revealed by a specific chemical probe, Zinquin. Chem Biol 1: 153-161.